Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PhRMA names general counsel

Executive Summary

Conan Grames will join the Pharmaceutical Research & Manufacturers of America as VP and general counsel on Feb. 6. Grames is replacing Bruce Kuhlik, who left PhRMA in May for Merck (1"The Pink Sheet" May 2, 2005, In Brief). Diane Bieri, who has been serving as acting general counsel, is now chief deputy general counsel. Grames has been chairman of the International Law Practice Section of Kirton & McConkie in Salt Lake City, Utah, where he was responsible for developing the Health Services Group at the firm. Prior to joining Kirton & McConkie, Grames served as VP-international policy and compliance at Bristol-Myers Squibb, where he spent 17 years in various senior positions in the legal division of the company...

You may also be interested in...



PhRMA general counsel moving to Merck

Pharmaceutical Research & Manufacturers of America General Counsel Bruce Kuhlik will leave the association May 13 to join Merck as VP and associate general counsel on May 23. Kuhlik has been with PhRMA since October 2002. In addition to providing business and regulatory advice at Merck, he will work on defending the company against litigation related to the withdrawn COX-2 inhibitor Vioxx...

Podcast: The Week In European Consumer Health Industry News, 8 March 2021

HBW editors Tom Gallen and David Ridley discuss the big issues in the European consumer health market from the past week. In this edition, they delve into probiotics, digital health and Bayer’s recent turnaround.

The Ins And Outs Of The EU's Approach To COVID-19 Vaccine Procurement & Exports

EU trade expert Hervé Jouanjean considers the reasoning behind the EU’s vaccine procurement approach and Italy's decision to block exports of AstraZeneca's  COVID-19 vaccine.

UsernamePublicRestriction

Register

OM010563

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel